SynthesisMolecular biology reports2025
Expanding the spectrum of ATP8A2 mutations: a new splicing variant and systematic review of CAMRQ4 syndrome.
Synthesis in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Novel Perspectives onEpigenomes · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCerebellar ataxia, mental retardation, and disequilibrium syndrome type 4 (CAMRQ4) is a rare autosomal recessive neurological disorder caused by biallelic variants in the ATP8A2 gene. It is characterized by severe psychomotor impairment, hypotonia or spasticity, and intellectual disability. Despite increasing case reports, the full phenotypic spectrum remain incompletely defined.
methodsWe report the case of a 7-year-old girl born to consanguineous parents, presenting with severe psychomotor delay, quadriplegia, and craniofacial dysmorphisms. Whole exome sequencing identified a novel splicing variant in ATP8A2 (NM_016529.6:c.1580-3C > G). In silico tools predicted a disruption of the canonical splice acceptor site. To confirm the splicing effect, RNA was extracted from peripheral blood, followed by cDNA synthesis and PCR amplification of the region flanking the variant. Products were analyzed via gel electrophoresis.
resultsExperimental validation revealed skipping of exon 18, confirming a significant impact on splicing and supporting the reclassification of the variant as "likely pathogenic" based on ACMG criteria (PM2, PP3, and now PS3). Additionally, a systematic literature review of published CAMRQ4 cases was conducted to delineate the clinical heterogeneity associated with ATP8A2 variants.
conclusionsThis case expands the mutational spectrum of ATP8A2 and provides strong evidence for the pathogenicity of a novel splicing variant. Our findings emphasize the clinical and genetic heterogeneity of CAMRQ4 and highlight the critical role of functional RNA studies in variant interpretation. Comprehensive genotype-phenotype correlation through systematic review enhances our understanding of ATP8A2-related disorders.
Indexed as
Identifiers
40312603What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.